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There is still controversy in the scientific field about whether certain types of cutaneous
human papillomaviruses (HPVs) are causally involved in the development of non-
melanoma skin cancer (NMSC). Deciphering the etiological role of cutaneous HPVs
requires – besides tissue culture systems – appropriate preclinical models to match
the obtained results with clinical data from affected patients. Clear scientific evidence
about the etiology and underlying mechanisms involved in NMSC development is
fundamental to provide reasonable arguments for public health institutions to classify
at least certain cutaneous HPVs as group 1 carcinogens. This in turn would have
implications on fundraising institutions and health care decision makers to force –
similarly as for anogenital cancer – the implementation of a broad vaccination program
against “high-risk” cutaneous HPVs to prevent NMSC as the most frequent cancer
worldwide. Precise knowledge of the multi-step progression from normal cells to cancer
is a prerequisite to understand the functional and clinical impact of cofactors that affect
the individual outcome and the personalized treatment of a disease. This overview
summarizes not only recent arguments that favor the acceptance of a viral etiology
in NMSC development but also reflects aspects of causality in medicine, the use of
empirically meaningful model systems and strategies for prevention.
Keywords: cutaneous papillomaviruses, hit-and-run mechanism, Mastomys coucha, causality, skin cancer,
animal models, NMSC
Abbreviations: AK, actinic keratosis; ALK, ALK Receptor Tyrosine Kinase; ATM, ataxia telangiectasia mutated; ATR, ataxia
telangiectasia and Rad3-related protein; BPV1, bovine papillomavirus 1; BRAFi, Inhibitors of the B-Raf Proto-Oncogene;
CDKN2A, cyclin-dependent kinase inhibitor 2A; cGMP, current good manufacturing practice; CKIT, KIT proto-oncogene
receptor tyrosine kinase; CREBBP, CREB binding protein (CREB, CAMP responsive element binding protein 1); DDR,
DNA damage response; E6AP, Ubiquitin Protein Ligase E3A; EGFR, epidermal growth factor receptor; FAT1, FAT
atypical cadherin 1; FGFR3, fibroblast growth factor receptor 3; HIPK2, homeodomain-interacting protein kinase 2;
HRAS, Harvey rat sarcoma virus oncogene; KA, Keratoacanthoma; KRAS, Kirsten rat sarcoma viral oncogene homolog;
MAML1, mastermind like transcriptional coactivator 1; McPV2, Mastomys coucha papillomavirus 2; MHC, major
histocompatibility complex; MmuPV1, Mus musculus papillomavirus type 1; MnPV, Mastomys natalensis papillomavirus;
NMSC, non-melanoma skin cancer; OTRs, organ transplant recipients; PIK3CA, Phosphatidylinositol-4,5-Bisphosphate
3-Kinase Catalytic Subunit Alpha; pRb, RB transcriptional corepressor 1; Pten, phosphatase and tensin homolog; SCC,
squamous cell carcinoma; TLR, Toll-like receptor; TP53, tumor protein P53 (human); Trp53, transformation related protein
53 (mouse).
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THE PROBLEM – A SERIOUS AND
COMMON DISEASE: NON-MELANOMA
SKIN CANCER
Non-melanoma skin cancer is the most frequent cancer in fair-
skinned individuals worldwide and its incidence has increased
during the last three decades (Welsh et al., 2011; Lomas et al.,
2012). There are up to 3 million new cases every year, whereby
women below 45 years are even more affected (Al-Dujaili et al.,
2017). Based on different UV exposure rates, there are also
geographical variations, with the highest incidence of NMSC in
Australia (Lomas et al., 2012). Although the metastatic potential
and the mortality rates in immunocompetent individuals are low
in comparison to malignant melanomas, NMSC has a strong
impact on the quality of life of the affected persons and the
financial burden on health care systems. Taking the United States
as an example, total annual expenses for NMSC medical care
amounts to 650 million dollars (Apalla et al., 2017). Hence, there
should be a quite obvious public health interest to understand and
to prevent this cancer entity.
Non-melanoma skin cancer principally refers to cancer
derived from keratinocytes (Small et al., 2016) and can be
further divided into basal cell carcinomas (BCCs) and squamous
cell carcinomas (SCCs), with relative frequencies of 80 and
20%, respectively (Eisemann et al., 2014). While BCCs are not
very different in their biological behaviors, SCCs show broad
histopathological diversities that are associated with markedly
different clinical outcomes. Depending on the immune status
of the patient, these may range from indolent tumors with
low metastatic capacity to aggressive tumors with high invasive
potential. Approximately 97% of invasive SCCs are found in
association with malignant progression of an actinic keratosis
(AK), considered as a precursor of SCCs. These lesions can
display erythematous, scaling, and rough patches. They can either
spontaneously regress, persist as a benign AK or progress to an
invasive SCC where cells infiltrate the basement membrane into
the dermis (reviewed in Yanofsky et al., 2011). TP53 is found to
be mutated in dysplastic AKs, indicating that functional loss is a
very early event, connected with loss of chromosomes including
the cell cycle regulator p16INK4A (Ratushny et al., 2012). To
define some general histopathological features, a committee of
European dermatologists has recently identified telangiectasia,
atrophy, and pigmentation disorders as the most reliable markers
for AKs (Dreno et al., 2017).
Other clinically common lesions are keratoacanthomas
(KAs) which can form spontaneously but, after a proliferative
and subsequent resting phase, have the tendency to regress,
apparently due to apoptosis. Histologically, a KA is an exo-
/endophytic growing squamous proliferative tumor with a
characteristic central keratin plug, surrounded by epidermal lips,
forming a relatively well-defined symmetrical structure (Takai,
2017). Of note, approximately 25% of KAs can develop into SCCs
(Sanchez Yus et al., 2000). Although still controversially discussed
in terms of whether a KA is a variant of SCC, other dermatologists
believe it represents a self-resolving benign epidermal lesion
(reviewed in Savage and Maize, 2014). This illustrates the current
discrepancies between histopathological phenotypes and deep
sequencing DNA profiles of respective specimens, since KAs and
SCCs are distinct entities at least by their unique molecular gene
signatures (Ra et al., 2015). Nonetheless, according to the “World
Health Organization Classification of Tumors” as a guideline
for pathologists in diagnostics, KAs are still regarded as a well-
differentiated SCC (LeBoit et al., 2006).
Another thought-provoking inquiry that has clinical
significance in the context of NMSC pathogenesis emerged
during the last years, when patients with advanced metastatic
melanomas were treated with BRAF inhibitors (BRAFi) (e.g.,
vemurafenib or dabrafenib) (reviewed in Gibney et al., 2013).
The off-target outcome of such drugs results in deleterious
dermatological side effects, histopathologically ranging from
verrucal keratosis, hair follicle changes, plantar hyperkeratosis,
KAs and finally cutaneous SCCs (Anforth et al., 2013).
Vemurafenib also has a photosensitizing activity (Boussemart
et al., 2013), consistent with the finding that most SCCs can be
detected at chronically sun-damaged skin regions (Hassel et al.,
2015).
ENDOGENOUS AND ENVIRONMENTAL
RISK FACTORS FOR NMSC
The Individual Genotype
Cancer in general is a multi-factorial disease and as individual
as the patient, a reasonable concept that is culminating in the
contemporary discourse of personalized medicine (reviewed in
Mavropoulos et al., 2014; Harwood et al., 2016). Referring to this
notion, meta-analyses of the current literature have deciphered
several risk factors that are either distinct in terms of an inherent
genetic predisposition of an individual patient and/or caused by
environmental factors (reviewed in Wang et al., 2014; Belbasis
et al., 2016). Individual risk factors for NMSC are age, family
history, pigmentation, polymorphisms within genes encoding
IL10, IL4R, TNF, or TNFR2 (Welsh et al., 2011), several inborn
genetic disorders like Xeroderma pigmentosum (Black, 2016),
the basal cell nevus syndrome (reviewed in Bresler et al., 2016)
or the WHIM (Wart, Hypogammaglobulinemia, Infection, and
Myelokathexis) syndrome, an autosomal dominant inheritance
immune deficiency, harboring mutations in the chemokine
receptor CXCR4 (Chow et al., 2010; Meuris et al., 2016).
Such patients show a high susceptibility for both cutaneous
and mucosal HPVs. Multiple warts can occur on hands
and feet, but also genital condylomata acuminata can be
found (Leiding and Holland, 2012). In the case of patients
suffering from the rare hereditary disease Epidermodysplasia
verruciformis (EV), mutations within at least two genes
of homologous transmembrane channel-like (TMC) proteins,
TMC6 (EVER1) and TMC8 (EVER2) were described (Lazarczyk
et al., 2009, 2012). These proteins are involved in zinc
homeostasis and are not only expressed in keratinocytes,
but also in lymphocytes, suggesting additional functions in
the immune response (reviewed in Kalinska-Bienias et al.,
2016). Due to their interaction with the Zn2+ transporter
protein ZnT-1, TMC6/8 can further modulate MAP kinases
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and in turn AP-1, a transcription factor involved in many
signal transduction pathways (reviewed in Lazarczyk and Favre,
2008).
Immune Status
Another important risk factor is iatrogenic immunosuppression
as SCCs appear 65–250 times more frequently in OTRs
compared to the general population (reviewed in Nindl and
Rösl, 2008; Vinzón and Rösl, 2015). Moreover, the frequency
of tumor formation correlates with the extent and duration of
immunosuppression (reviewed in Euvrard et al., 2003; Hampton,
2005). It is estimated that up to 40% of OTRs will develop
skin cancers within the first 10 years of transplantation and
up to 80% after 20 years (Rangwala and Tsai, 2011). Although
early detection of NMSC evidently improves the overall survival
rate, a 20 year follow-up study including more than 85,000
patients showed that OTRs have a much worse prognosis and
a higher mortality rate as compared to immunocompetent
individuals (Acuna et al., 2016). The exact physiological reason
is still unexplained, but it is assumed that tumors are simply
more aggressive in an immunosuppressive environment since
substances like cyclosporine both promote tumor invasion
and favor neovascularization (reviewed in Geissler, 2015).
Immunosuppressive drugs apparently also impair the DDR
and counteract p53-dependent cellular senescence (Wu et al.,
2010; Kuschal et al., 2012). Since SCCs develop mostly within
sun-exposed areas, UV exposure is immune compromising
(reviewed in Nakad and Schumacher, 2016). Despite the obvious
increase of NMSC, population-based studies of skin cancer
mortality after organ transplantation and in immunocompetent
individuals are still scant (John et al., 2016). This is mainly due to
geographic variability of incidence rates and, most importantly,
the exclusion of NMSC from central cancer registries records
(reviewed in Apalla et al., 2017) as recently noticed in the
“European Code against Cancer: Infection and Cancer” (Villain
et al., 2015). Such an obvious gap in cancer documentation should
be filled as exemplified by initiatives such as the “Keratinocyte
Carcinoma Consortium” (Madeleine et al., 2017), because NMSC
incidence is increasing worldwide and caused by daily and
life-long risk factors such as UV exposure and skin infections
(Garrett et al., 2016; Prasad and Katiyar, 2017).
Sun Exposure
Another major environmental risk factor that has to be taken into
account for the development of NMSC is the cumulative lifelong
exposure to UV light, as well as sunburns in youth (Kennedy
et al., 2003). UV light is divided into three categories according
to its energy (wave length), which are UVA (320–400 nm),
UVB (290–320 nm), and UVC (100–290 nm). UVC is almost
completely filtered by the atmospheric ozone layer, which also
shields up to 90% of UVB radiation. Thus, only UVA and
UVB play roles as risk factors. Although not penetrating in
the skin as deep as UVA, due to its higher energy output,
UVB is more harmful and can damage cells heavily (reviewed
in Seebode et al., 2016). UVB has also additional deleterious
side-effects on the immune system, for example, by perturbing
the function of antigen-presenting cells and in turn increasing a
local immunodeficiency (reviewed in Prasad and Katiyar, 2017).
Thus, cumulative UV exposure can contribute to skin tumor
development by impairing immune surveillance of the skin
(Maglennon et al., 2014). UV has also direct effects on the
DNA, leading to a covalent joining of adjacent pyrimidines
to form cyclobutane pyrimidine dimers (CPDs). Due to the
misincorporation of an adenine at the position complementary
to the UV DNA damage, CPDs predominantly lead to C→T
transitions (≥60%) and rarely to CC→TT transitions (5%),
leaving characteristic signatures within the DNA that can
be detected in the landscape of SCCs upon whole genome
sequencing (reviewed in Brash, 2015).
However, it is still not clear how to functionally rank
the significance and frequencies of such mutations since the
appearance of NMSC is, like other forms of cancer, the result of a
multi-step process in which the temporal/spatial order and the
impact on tumor formation cannot retrospectively be defined.
Moreover, comparatively little is known about the temporal
combinatory linkage of altered gene expression within a cellular
network, thus contributing to the individual manifestation of a
tumor (Krogan et al., 2015). Notably, deep-sequencing analyses
of normal skin sections of persons with different histories of
sun exposures even revealed identical UV specific signatures
in their genome with exactly the same genes affected as later
found in SCCs or BCCs (Martincorena et al., 2015). The reasons
why such mutations are tolerated in normal cells suggest a
counter-selective environment consisting of stromal, endothelial,
and inflammatory components that prevent the outgrowth of
clones finally forming a tumor. Considering recent concepts,
cancer is not simply a linear route, but a highly flexible
and emergent adaptation process of certain cells where clonal
expansion is following according to evolutionary principles that
limit the predictability of therapeutic outcomes (reviewed in
Greaves, 2015; Lipinski et al., 2016; Davis et al., 2017).
Cutaneous Papillomaviruses
Since individuals are “open systems,” the most critical exogenous
risk factor for NMSC is not only UV exposure, but also
infections with papillomaviruses. These target keratinocytes of
the skin and mucosa of different vertebrate species, including
humans. Up to date more than 200 human papillomavirus
(HPV) types are known according to the PaVE database1 (Van
Doorslaer et al., 2017), which are associated with different clinical
manifestations. Genital HPVs cause diverse lesions ranging from
benign warts (for “low-risk” HPV types) to different malignancies
(for “high-risk” types) of which cervical cancer is the most
prominent (zur Hausen, 2002; McLaughlin-Drubin et al., 2012).
On the other hand, there is also a wide range of cutaneous
HPV types that have been associated with diverse skin diseases
(reviewed in Grce and Mravak-Stipetic, 2014). Including more
than 100 healthy human volunteers in a broad study of
meta-genomic analyses, whole-genome shotgun sequencing
revealed an overall HPV prevalence of 69% in the skin, followed
by the vagina (42%), the mouth (30%), and the gut (17%)
(Ma et al., 2014). Another study even demonstrated that more
1https://pave.niaid.nih.gov
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than 95% of all viral sequences detected in skin samples belong
to the papillomavirus family, mostly to the beta-and gamma
genera. Here, also co-infections could be discerned, which
leads to speculation about potential temporal inclusion/exclusion
interaction mechanisms between different HPV types in the same
cell that may modulate the immune response and in turn viral
persistence (Bzhalava et al., 2014).
High prevalence of cutaneous HPV can be already detected
in skin of infants and young children, indicating that viral
exposure occurs very early in life (Antonsson et al., 2003).
Recurrent types are HPV2, 7, 27, 57 (alpha genus), HPV23 and
75 (beta genus), HPV4 and 65 (gamma genus) and HPV1 (mu
genus) that typically cause only benign lesions such as common
warts (verrucae vulgaris), plantar warts (verrucae plantaris), and
flat warts (verruca plana) (Jablonska et al., 1997; Cardoso and
Calonje, 2011; Bruggink et al., 2012) which usually spontaneously
regress (van Haalen et al., 2009). However, they can represent a
serious problem for immunocompromised individuals, especially
OTRs, who frequently suffer from confluent wart formation all
over the body. The prevalence within this population ranged
from 48 to 92% in the first 5 years after immunosuppression
(Jablonska et al., 1997; Wang et al., 2014). The HIM study
(“cutaneous HPV infection in healthy men”) reported a different
median time of incidence (=newly diagnosed in skin) and
duration of persistence of beta and gamma HPV infections
ranging between 6–8 and 6–11 months, respectively. Older
volunteers showed a significant higher association with prevalent
and persistent HPV infections (Hampras et al., 2014). However,
merely monitoring the skin for the presence of a viral DNA does
not allow any conclusions about an ongoing infection and the
exposure of viral antigens to the immune system. Such questions
can only be answered when combined with immunological
studies to get estimations about the rates of seroconversion and
the serodynamics of cutaneous HPV infections (Rahman et al.,
2016), an important criteria when preclinical models are used (see
below).
“High Risk” Cutaneous HPVs?
The term “infection” indicates the presence of a microbe which
can be pathogenic, commensal or opportunistic (reviewed in
Casadevall and Pirofski, 2000). Hence, considering the individual
complexity of the human skin virome that in turn also represents
an interactome with a defined microbial environment (Hannigan
et al., 2015), it is a huge challenge of modern biomedicine to
dissect such networks in terms of functionality and causality.
Indeed, the skin is an open ecosystem, colonized by a broad
spectrum of bacteria and viruses whose landscape and impact on
local immunity change during their individual life span and by
environmental factors (Belkaid and Segre, 2014). We still do not
understand how these different constituents dynamically interact
with other microorganisms colonizing the skin, what the selective
advantage of such a commensalism is, how the virome in turn
affects the transcriptome of the skin (Edqvist et al., 2015), form
the individual immunophenotype and how these properties vary
with respect of individual skin types, under immunosuppression
or UV exposure (Virgin, 2014). The categories commensal,
pathogenic or opportunistic are helpful notions in the context
of tumor viruses (Moore and Chang, 2017). Accordingly,
commensal tumor viruses (e.g., EBV or cutaneous HPVs), are
almost ubiquitously spread and usually do not cause symptoms.
Contrarily, pathogenic tumor viruses are not so frequent and
acquired, for instance via sexual intercourse or blood transfusion
(e.g., high-risk mucosal types of HPV or Hepatitis B virus,
HBV). Due to their ubiquitous prevalence in the general healthy
population, there is still skepticism whether cutaneous HPVs
are causally involved in NMSC development. However, there
are many epidemiological and mechanistic in vitro/in vivo data
showing increasing evidence that at least some commensal HPVs
represent an essential, if not even a decisive factor for this type
of skin cancer, especially for SCC (Madeleine et al., 2013; Wang
et al., 2014; Chahoud et al., 2016).
Historically, the oncogenic potential of beta-type HPV
infection (e.g., HPV5 and HPV8) in NMSC has been originally
identified in patients suffering from EV, characterized by an
increased susceptibility to viral infection (Orth, 2006). The
oncogenic and transforming capacity of the EV-HPVs has not
only been shown in transgenic mouse models (Schaper et al.,
2005; Pfefferle et al., 2008; Viarisio et al., 2011), but also in
organotypic raft cultures under in vitro conditions (Borgogna
et al., 2012; Heuser et al., 2016b; Marthaler et al., 2017).
Beta-type papillomaviruses were also detected in NMSCs of
non-EV patients, although the viral loads are usually very low. It
is assumed that the reservoirs for latent infection are hair follicle
stem cells (Hufbauer et al., 2013). Different studies have reported
HPV DNA in 30–50% of NMSCs from immunocompetent
persons (Harwood et al., 2006), whereas in immunosuppressed
patients this figure goes up to 90% (Harwood et al., 2000; Arnold
and Hofbauer, 2012). Transcriptionally active beta-type HPVs
can be found in premalignant lesions such as AKs (Borgogna
et al., 2014) but also in normal skin and plucked eyebrow hairs
suggesting a functional correlation between the presence of viral
DNA and an increased risk of NMSC (Neale et al., 2013). UV
exposure per se can also directly stimulate viral transcription
of the EV-types HPV5 and HPV8 (Akgül et al., 2005b), while
other cutaneous types such as HPV38 E6/E7, for instance, can
block UV-induced expression of the toll-like receptor 9 (TLR9),
normally responsible for endosomal sensoring of exogenic DNA
(Pacini et al., 2017). This shows the complexity of a virus–host
interaction, demonstrating several modes of action by different
HPV types to interfere with signal transduction pathways of
the host cell. Moreover, in contrast to anogenital tumors, there
are also SCCs that either completely lack HPV or not all
cells are virus-positive (Neale et al., 2013), indicating that viral
oncoprotein expression is not necessary to maintain a malignant
phenotype (reviewed in Arron et al., 2011; Hufbauer and Akgül,
2017).
SOME REFLECTIONS ABOUT THE
“CAUSALITY” OF INFECTIONS
The lack of HPV in cancerous skin lesions is in apparent
contradiction to the so-called Henle-Koch’s postulates that were
traditionally used as criteria for “causality” of an infection
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(reviewed in Inglis, 2007). However, one should keep in
mind that the conception of causality is a term historically
referring to physical properties of the inanimate matter and
not to living systems. Physicists deal with reproducible regular
events and experimental settings, while cancer research is
investigating “anomalous” scenarios, sometimes rare disorders
in terms of cancer development which are, as aforementioned,
multi-factorial and individually shaped. Hence, the simple
detection of an infection or frequent mutations found in
genetically non-predisposed persons cannot be considered as
“causal,” because they are only contingent and the individual
clinical outcome is determined by many additional factors
(reviewed in Greaves, 2015). More correct in an epistemic sense
is the word “etiology,” since this term has a more suitable
connotation, reflecting more the complexity of an organism
and not implying necessarily a direct and quite obvious causal
relationship.
Nonetheless, in principle the Henle-Koch’s postulates state
that an infectious agent should be consistently detected in the
respective lesions, it should be isolated and its re-inoculation
should induce the same symptoms or clinical manifestations.
However, these postulates have their limitations, because they
are not considering multi-factorial events in the development
of a disease (reviewed in Edwards and Rohwer, 2005; Virgin,
2014; O’Malley, 2016). Moreover, they also do not reflect
asymptomatic, latent or persistent infections, all states in
which HPV DNA can exist (Sudenga and Shrestha, 2013).
Anecdotally, Robert J. Huebner, Chief of the Laboratory of
RNA Tumor Viruses (NCI) recognized this inadequacy by
referring it as the “The Virologist’s Dilemma” (Huebner, 1957).
As a consequence, he paved the way for the inclusion and
particularly the acceptance of epidemiological data to corroborate
the involvement of a virus as a cause for a specific disease (Vonka,
2000).
The progress in molecular technologies and immunological
methods (Falkow, 2004) therefore led to a revision of these
criteria, by both including epidemiological and molecular data
as well as terminologies like “plausibility” (=whether a causal
relationship makes biological sense) and “coherence” (=asking
whether causality is compatible with present knowledge of
the disease), respectively (Fredricks and Relman, 1996). Such
an extension avoids an important category of empiricism,
namely the notion of “falsification” and the consequential
dump of a theory in favor of another (Buchanan et al., 2006).
Revised criteria rather allow the inclusion of other scenarios
to explain the absence of viral sequences in some SCCs. For
instance, considering the importance of cell–cell communication
in a tumor microenvironment, it is also conceivable that a
small fraction of HPV-positive cancer cells secrete paracrine
acting vesicles (e.g., exosomes) that may stimulate abnormal
proliferation of surrounding virus-negative cells and in turn
tumor growth (Dalla Pozza et al., 2017; Harden and Munger,
2017). However, the strongest arguments for at least an obligatory
initial function of certain viruses in cancer development are
vaccination strategies where the prevention of tumor formation
is the most stringent read-out criteria for the success of a vaccine
(Moore and Chang, 2017).
Hence, the question of an etiological or merely an
opportunistic role of beta-HPV types in skin cancer development
is accomplished in a concept, referred as the “hit-and-run”
mechanism of microbe/virus induced carcinogenesis (reviewed
in Galloway and McDougall, 1983; Iwasaka et al., 1992; Niller
et al., 2011; Hufbauer and Akgül, 2017). Alternatively, the
term “indirect carcinogen” was suggested (Mossman et al.,
2004), but this semantically points more toward a substance
or an irradiation event as environmental carcinogen than to
an infectious agent and confuses the notion of prophylactic
vaccination to prevent tumor formation induced by an “indirect”
carcinogen. However, a “hit-and run” model of gene regulation
is not without precedent. As already suggested several decades
ago (Schaffner, 1988), recent experiments indeed showed that
certain transcription factors (e.g., bZIP1) epigenetically change
the histone code after transient binding (“hit”) that allows the
assembly of transcription complexes to continue gene expression
after its dissociation (“run”) (reviewed in Varala et al., 2015).
Whether certain HPV types also use this mechanism remains to
be elucidated.
Nevertheless, numerous seroepidemiological reports support
the notion of an association between beta-HPV infection and
SCC or its precursors (Andersson et al., 2012; Chahoud et al.,
2016), despite the occasional absence of the viral DNA within
malignant lesions. Here, another distinct property between
mucosal and cutaneous HPV types may account for the
occasional loss of viral DNA during skin carcinogenesis, namely
the physical state. In contrast to anogenital cancer, cutaneous
HPVs do not integrate into the host genome and persist as
extrachromosomal elements in a defined copy number. Since
HPVs completely depend on the host cell replication machinery,
UV-induced DNA damage and the mode of accompanying repair
mechanisms may disrupt the maintenance of episomal DNA
during viral persistence (reviewed in Doorbar, 2016; Bristol et al.,
2017; Wendel and Wallace, 2017).
HOW CAN A “HIT-AND-RUN”
MECHANISM BE EXPLAINED?
Accepting tentatively an etiological function of beta-HPV
in conjunction with UV exposure in NMSC development,
several studies have identified different mechanisms that may
reasonably explain a viral contribution to a “hit-and-run”
mode of carcinogenesis. Cutaneous HPVs infect and persist
as extrachromosomal genomes in basal keratinocytes especially
around hair follicles (Weissenborn et al., 2012) which are a
reservoir for stem cells with different properties (Jaks et al., 2010).
During wound healing (Donati et al., 2017) and skin cancer
development in transgenic mice expressing the complete early
region of HPV8 (Lanfredini et al., 2017), these cells become
activated and start to proliferate.
The main targets of mucosal HPVs are p53 and pRB, which
is sufficient to transform the host cell and initiate uncontrolled
proliferation (see Doorbar et al., 2012 and references herein), by
impairing many downstream pathways such as cell cycle arrest,
metabolism, apoptosis, and cross-talks to the immune system
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(Harris and Levine, 2005; Rozan and El-Deiry, 2007; Moody
and Laimins, 2010). In contrast, cutaneous papillomaviruses
developed several alternative strategies to interfere with their
host cells: instead of binding E6AP to facilitate p53 degradation
as alpha type HPVs, E6 of most other HPV genera, amongst
them the cutaneous types HPV1 and HPV8, binds to MAML1
to inhibit NOTCH signaling, a feature also shared by animal
PVs (e.g., BPV1, MmuPV1, and MnPV) (Brimer et al., 2012,
2017; Meyers et al., 2017). MAML1 together with the histone
acetyltransferases p300 and CREBBP can form a transcription
complex that activates this pathway (Rozenblatt-Rosen et al.,
2012). Amongst its function as a tumor suppressor, NOTCH
drives differentiation of keratinocytes and is therefore found
to be frequently mutated in cutaneous SCCs (Pickering et al.,
2014; South et al., 2014). An impairment of this pathway either
by mutations or by intervention of HPV keeps the cell in
a proliferative state and promotes tumorigenesis. HPV5 and
HPV8 additionally interfere with host cell differentiation by an
E6-mediated degradation of p300, which in turn decreases the
expression of keratin 1 and 10 and involucrin (Howie et al.,
2011).
Furthermore, HPV38 E6 binds p300 thereby preventing
p53 acetylation at lysine 382 and blocking p53-mediated
apoptosis (Muench et al., 2010). HPV38 E6 can also increase
the expression of the N-truncated isoform of p73, lacking a
transactivation domain. 1Np73 in turn competes with p53
activity that may perturb apoptosis and the eradication of
damaged HPV-positive cells (Caldeira et al., 2003). A recent
study further showed that by targeting p300, HPV8 E6 maintains
a proliferating state of the host cell by downregulating the
CCAAT/enhancer-binding protein (C/EBPα) and decreasing the
expression of microRNA-203, a repressor of 1Np63 expression
(Marthaler et al., 2017). While p63, the master regulator of
epithelial stemness, can induce cell cycle arrest and apoptosis like
p53 and p73,1Np63 can act in a dominant-negative manner and
maintain proliferation (reviewed in Candi et al., 2015). Indeed,
certain beta-HPVs target central hubs within the cellular network
that control differentiation, senescence as well as apoptosis, which
reasonably explains the capacity of these viruses to stimulate
proliferation of undifferentiated cells. Such effects on tissue
homeostasis are of profound importance in NMSC development,
particularly when HPV-infected skin is cumulatively exposed
to UV.
UV exposure under physiological circumstances induces p53
stabilization and activation that leads to a cell cycle arrest and
DNA repair or – at higher dosages – to apoptosis (reviewed in
Zuckerman et al., 2009). Perturbed p53 function in turn leads
to a gradual accumulation of genetically altered cells, thereby
promoting the development of NMSC (Feltkamp et al., 2008).
While high-risk mucosal types directly target p53 itself after DNA
damage, cutaneous beta-HPVs affect a plethora of DDR proteins
downstream of p53 (White et al., 2014; Wendel and Wallace,
2017). An important protein that links the ATM/ATR pathway
to p53-induced apoptosis is the conserved Ser/Thr kinase HIPK2
(Matt and Hofmann, 2016). Upon severe UV damage, HIPK2
forms a complex with p53 and the CBP acetyltransferase
leading to HIPK2-mediated p53 phosphorylation at serine 46
and CBP-mediated p53 acetylation at lysine 382 and finally
a strong p53 activation with induction of pro-apoptotic gene
expression (reviewed in Bitomsky and Hofmann, 2009; Matt
and Hofmann, 2016). As shown for one of the most prevalent
HPV types found in skin (de Koning et al., 2009), HPV23
E6 can inhibit HIPK2-mediated phosphorylation of p53 in
response to UV damage (Muschik et al., 2011). Intriguingly,
HIPK2 also controls the number of stem and progenitor cells
in the skin (Wei et al., 2007), the reservoir for cutaneous HPVs
(reviewed in Egawa et al., 2015). Moreover, HIPK2-deficient
mice show an enhanced susceptibility to develop SCCs (Wei
et al., 2007) consistent with decreased levels HIPK2 expression
in KAs and SCCs compared to AK (Kwon et al., 2015).
Additionally, beta-HPVs can abrogate UV-induced pyrimidine
dimer excision (Giampieri and Storey, 2004) or target the
pro-apoptotic protein Bak for proteolytic degradation (Jackson
et al., 2000; Underbrink et al., 2008; Holloway et al., 2015). In any
case, the interference with the DDR and pro-apoptotic pathways
can promote long-lasting effects on genomic instability and
favors the accumulation of damaged cells (reviewed in Wendel
and Wallace, 2017).
Moreover, UV-activated EGFR signaling which causes
keratinocyte hyperproliferation and hyperplasia of the skin
(El-Abaseri et al., 2006) is enhanced by HPV8 E6, thereby
contributing to SCC formation (Taute et al., 2017). Furthermore,
HPV5 and 8 E7 alter beta-catenin and zona occludens-1 anchor
proteins which disturb cellular adherence and tight junctions
(Heuser et al., 2016a). Their reorganization imbalances tissue
homeostasis and lead to epithelial-mesenchymal transition
(EMT) (Polette et al., 2007), also suggesting a role in NMSC
development (reviewed in Chen et al., 2016). This is in line
with an HPV8 E7-mediated upregulation of metalloproteases
that remodel the extracellular matrix (Akgül et al., 2006) to
facilitate migration and invasion of HPV8-positive cells (Akgül
et al., 2005a). Furthermore, HPV8 E7 upregulates fibronectin,
another EMT marker (Lee et al., 2006), by inducing a switch
from E-cadherin to N-cadherin expression in suprabasal cell
layers of organotypic skin cultures, considered to be a primary
event in invasion of carcinoma cells (Heuser et al., 2016b).
As soon as HPV-infected altered squamous cells invade deeper
layers and undergo EMT, it is likely that HPV replication,
known to be highly dependent on cell differentiation, cannot be
maintained (reviewed in Doorbar et al., 2012). Consequently,
viral presence is no longer necessary for malignant progression,
since the tumor becomes heterogeneous in terms of acquiring
additional mutations. Despite different modes of action for
mucosal and cutaneous HPVs, the outcome is similar: in
the case of cervical carcinoma, HPV is integrated into the
host cell genome but maintains the transformed phenotype
by continuous E6/E7 expression (reviewed in Doorbar et al.,
2012). Conversely, cutaneous HPVs interfere with their host
cell apparently in the beginning of the multi-step process of
carcinogenesis, finally leading to an intracellular environment
counteracting episomal DNA replication. This may explain why
lower or no viral loads are detected in SCCs as compared to pre-
malignant lesions (Weissenborn et al., 2012). In any case, this is
a “dead end” for both mucosal and cutaneous HPVs, since the
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permissive cycle is interrupted and no new virus progenies can
be formed.
THE IMPORTANCE OF PRECLINICAL
MODELS FOR INFECTIOUS AGENTS –
SOME GENERAL CONSIDERATIONS
Models in bioscience are indispensable to reduce the complexity
of a disease manifested in patients, but of course they also have
their inherent limitations (Anisimov et al., 2005; Mazzocchi,
2008; Dougherty and Shmulevich, 2012). Moreover, in contrast
to the empirical supposition of a working hypothesis as “right” or
“wrong,” models can also be tentatively categorized as “relevant”
or “irrelevant” for the investigation of a particular scientific
question or even a multifactorial disease. Since there is a
strong social pressure on basic research to bring reproducible
laboratory results into the clinic (Begley and Ellis, 2012), there
are indeed many recent initiatives to improve this transfer by
validating the relevance and impact of in vitro and in vivo
models with respect of their translational applicability (Denayer
et al., 2014; Day et al., 2015; Dolgos et al., 2016; Horvath et al.,
2016).
Animal experiments for infectious agents like
papillomaviruses are also indispensable (Doorbar, 2016;
Christensen et al., 2017) and should reflect as much as possible
the molecular and histological key features of a disease as
found in patients (reviewed in Greek and Menache, 2013).
Nevertheless, besides pragmatic reasons in working with easily
managing laboratory animals (e.g., rodents) (reviewed in Hu
et al., 2017; Uberoi and Lambert, 2017), there are several other
important criteria for validation and predictability to guarantee
a successful clinical translation. They can be summarized as
follows (Kern, 1982; Greek and Menache, 2013; Denayer et al.,
2014):
1. The infectious agents should have the same species specificity,
tissue tropism and genome organization as their human
etiological counterparts.
2. The natural infection mode should be similar. This is of
particular importance with respect of the extent and spread
of an infection since it may affect both the time course of
seroconversion as well as the pathological outcome of the
disease.
3. The infectious agent should accomplish the revised
Henle-Koch criteria in terms of etiology (Fredricks and
Relman, 1996; Falkow, 2004; Mossman et al., 2004). Here,
some restrictions have to be considered, especially in the light
of novel insights into the organization of individual human
virome that can be changed in a time-dependent manner
(Virgin, 2014; Gentile and Micozzi, 2016; Vouga and Greub,
2016).
4. The viral inoculum in an experimental infection should not
over stimulate the immune system (Kern, 1982).
5. The animal should be immunocompetent and specific
antibodies to the respective agents normally absent before
exposure. Although especially inbred rodent systems do
not necessarily completely mirror human immunology
(reviewed in Mestas and Hughes, 2004), they still allow
dissecting virus–host interactions in terms of acute
and chronic/persistent infections in correlation with the
serological response.
6. Depending on immune surveillance in the case of tumor
formation, the same lesions should appear, ideally in the same
time frame relative to the median life time of the animals (“face
validity”).
7. Since cancer is a multi-factorial process, the animal model
should also allow the inclusion of additional non-genetic risk
factors for a disease (e.g., immunosuppression, UV exposure),
leading to an enhanced tumor formation.
8. Having identified a potential infectious agent, subsequent
vaccination of animals should prevent the disease. Hence,
preclinical models ideally should develop the same clinical
manifestations as found in patients, an important read-out
criterion for the success of a vaccine to be transferred into the
clinic (Moore and Chang, 2017).
9. To be valid as a preclinical model, a scoring system should
be applied that includes the careful selection of the animal
species, the degree of reflecting a disease, face validity,
complexity, and predictability (Denayer et al., 2014).
HOW DO THE CURRENT RODENT
MODELS FOR CUTANEOUS HPVS FIT
TO THESE CRITERIA?
Transgenic Mice
Transgenic mice are suitable model systems for most research
fields and have also contributed enormously to our mechanistic
knowledge about mucosal and cutaneous PVs (reviewed in
Doorbar et al., 2015; Lambert, 2016; Santos et al., 2017).
Current genome editing technologies make them relatively easy
to generate and to manipulate (Rocha-Martins et al., 2015).
The transgene, regularly containing the open reading frames
(ORFs) of E6, E6/E7 or the complete early region of the
selected HPV type is typically expressed under control of the
keratin 14 promoter which facilitates constitutive oncogenic
expression in cycling epithelial cells. The composition of the
ORFs and the varying oncogenic potential of cutaneous HPVs
significantly influence the outcome of experiments, e.g., the
tumor induction. For example, mice harboring the complete
early region of HPV8 spontaneously develop papillomatosis,
acanthosis and hyperkeratosis, epidermal dysplasia and, to
lower frequency, SCC formation (Schaper et al., 2005). Here,
overexpression of the early region leads to a clonal expansion
of a population of Lrig1+ keratinocyte stem cells in the
hair-follicles that is accompanied by a switch of p63 to its
1Np63 isoform, lacking the N-terminal transactivation domain
(Lanfredini et al., 2017). This in turn interferes with the function
of p63 and p73 to induce cell cycle arrest and apoptosis. It
also impairs the cellular differentiation program and drives
proliferation (reviewed in Candi et al., 2015). Due to the
involvement of Lrig1+ stem cells in wound healing (Donati et al.,
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2017), it is not surprising that development of papillomatosis
could be also accelerated after UV exposure, further suggesting
a synergistic effect between HPV8 and exogenous factors
(Marcuzzi et al., 2009). Furthermore, via targeting of C/EBPβ,
HPV8 E7 also suppresses the expression of the CC chemokine
ligand 20 (CCL20), which plays a pivotal role in the recruitment
of Langerhans cell precursors into the epidermis (Sperling et al.,
2012). Hence, considering all these scenarios, the impact of
HPV8 on cell differentiation and innate immunity can reasonably
explain how a viral infection commits cells to malignant
transformation.
The mechanisms by which cutaneous HPVs interfere with
their host cell, e.g., by disturbing p53-connected pathways (White
et al., 2014) or the DDR to UV, can lead to different outcomes
of experiments (Dong et al., 2008; Hufbauer et al., 2011; Viarisio
et al., 2011; Holderfield et al., 2014). For instance, as shown
recently for HPV49 E6/E7 transgenic mice, these animals are
less susceptible to form UV-induced tumors as compared to
mice expressing other beta-HPVs, but are prone to chemically
induced carcinogenesis of the upper digestive tract (Viarisio
et al., 2016). Moreover, in contrast to the HPV8 model where
one UV dose was sufficient to induce skin lesions (Marcuzzi
et al., 2009), HPV38 E6/E7 transgenic mice require an extended
irradiation protocol (Viarisio et al., 2011), mimicking a more
natural situation as found in humans after life-long UV exposure
(Maglennon et al., 2014). Tumors obtained in the HPV8 model
after a single UV dose lack mutations in the Trp53 and Notch1
loci, but these were present after cumulative UV exposure in
HPV38 mice. Notably, SCCs appeared much earlier in the
latter model when UV irradiation and BRAFi treatment were
combined. Intriguingly, although no HRAS and KRAS mutations
were found in these tumors, the mitogen-activated protein kinase
pathway was activated (Viarisio et al., 2017). Monitoring clinical
SCC samples obtained from melanoma patients, it seems that
HRAS mutations and the presence of HPV is mutually exclusive
(Holderfield et al., 2014), a constellation that is reminiscent of
transgenic mice expressing HPV38 E6/E7 constitutively.
Considering the concept of a “hit-and-run” mechanism
during tumorigenesis, transgenic models are obviously not fully
suitable when used in a conventional way by constitutive
transgene expression. However, Viarisio et al. (2018) recently
were able to overcome this problem by knocking out the HPV38
E6/E7 cassette via Cre-lox recombination as soon as UV-induced
lesions appeared. After this, SCCs continued growing even
without oncogene expression, clearly demonstrating that viral
presence was no longer required to maintain the tumorigenic
phenotype. Moreover, these SCCs acquired a large panel of
potential “driver” mutations within Trp53, Notch1, and other
genes (Viarisio et al., 2018) that can also be observed in human
and murine SCCs (Pickering et al., 2014; Chitsazzadeh et al.,
2016).
Although transgenic and knock-out models definitely have
their justification when investigating potential principles of an
in vivo virus–host interaction, concerns may be raised as they
only reflect parts of the whole picture and do only partially,
if at all, fulfill the above mentioned criteria to guarantee a
successful clinical translation. The described examples are mostly
typical “gain-of-function” studies, where the viral transgene
is integrated and controlled by a heterologous promoter,
thereby not mimicking the physiological gene dosage and
the physical state of the viral DNA which normally persists
extrachromosomally in the host cell. Additionally, the encoded
transgenic proteins, provided there is no conditional gene
expression, are self-tolerant and do not mirror a proper immune
response against the corresponding genuine antigens expressed
during a natural infection (Walrath et al., 2010). Moreover,
according to quantitative trait locus (QTL) mapping analysis for
cancer susceptibility loci, inbred strains of mice tremendously
vary in their ability to develop tumors (Fleming et al., 2013).
Hence, although being extremely helpful, experiments with
transgenic mice have to be complemented with natural infection
models to get also insight in immunological aspects, particularly
allowing the production of appropriate vaccines to prevent
NMSC (Vinzón and Rösl, 2015).
Natural Model Systems
Restricting this overview only to rodent systems, and also
considering the above mentioned criteria for a relevant
preclinical model, the MmuPV1/ mouse model (reviewed in
Hu et al., 2017) is one of the most attractive, since the mouse
is not only the best-characterized laboratory animal, but can
also be infected by a virus isolated from the same species.
Although just discovered in 2011, Xue et al. (2017) recently
published a full transcription map of MmuPV1, providing a
basis for a further characterization of viral proteins and their
function in skin tumor formation. Moreover, first vaccination
studies have been carried out in this system (Jiang et al., 2017).
However, even with the MmuPV1/mouse model, the setup of
a natural infection followed by a complete viral life cycle in a
normal and immunocompetent host is unfortunately still not
completely fulfilled. In this model, for instance, lesions appear
only when infecting mice with high and, in comparison to
humans, non-physiological amounts of virus particles at certain
sites like the tail and muzzle, while the back skin is relatively
resistant (Handisurya et al., 2013, 2014; Wang et al., 2015). This
may be attributed to differential expression of MHC molecules,
the presence of Langerhans cells and variations in the keratin
network (Sundberg et al., 2014; Quigley et al., 2016), supporting
the importance of the local immune surveillance (Da Silva et al.,
2014) at the region of infection. These differences may also cause
inappropriate conditions for virus particle formation that have to
be overcome by a high infection rate, since fewer progenies could
be detected in back skin than in mucosal tissue, despite equal
viral DNA loads in both regions (Cladel et al., 2017). Cutaneous
MmuPV1-induced tail papillomas contained high amounts of
viral DNA (Uberoi et al., 2016), but no SCCs lacking MmuPV1
DNA are formed in immunocompetent animals that allow to
study a “hit-and-run” mechanism as proposed.
Another preclinical model that is used to explore the impact
of cutaneous papillomaviruses on skin carcinogenesis is the
African multimammate mouse Mastomys coucha, formerly
taxonomically classified as Mastomys natalensis (Figure 1;
Kruppa et al., 1990). These animals belong to the Muridae family
and are naturally infected with MnPV and McPV2, which – like
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cutaneous and genital HPVs – infect epidermal and mucosal
tissues, respectively (Muller and Gissmann, 1978; Nafz et al.,
2008). MnPV can spontaneously induce epithelial lesions of
the skin (mainly papillomas and KAs), while McPV2 causes
anogenital lesions like condylomata at the anus, vulva, and penis,
respectively. Similar to cutaneous HPVs, MnPV and McPV2
persist as episomes without any indication of integration but –
depending on the type of lesion – in different copy numbers (Nafz
et al., 2008). Considering the natural infection mode, M. coucha
acquire the virus early after birth, as MnPV DNA is found
in the skin of four-week-old animals where at the same time
seroconversion is taking place (Schäfer et al., 2011).
Similar to cutaneous HPVs, the MnPV genome lacks an ORF
for E5 (de Villiers et al., 2004) while parts of the E6, E1, and
L1 genes are phylogenetically related to HPV types associated
with EV (Tan et al., 1994). MnPV-induced benign lesions do not
spontaneously regress but have the capacity to transform to SCCs
(Reinacher et al., 1978; Vinzón et al., 2014). The exo-/endophytic
keratinized lesions contain high numbers of episomal virus
genomes (Figures 1B–D) and – similar to cutaneous HPVs –
do not show any sign for integration (Amtmann et al., 1984;
Hasche et al., 2017). As the animals are immunocompetent,
E2-specific antibodies serve as an early infection marker found
already in four-week-old animals, while L1-specific antibodies
appear later, correlating with the appearance of skin lesions
(Schäfer et al., 2011). Having a virus-free colony of M. coucha
as control, the animals also served as preclinical model for
the development of MnPV-specific vaccination strategies both
under normal and immunosuppressed conditions (Vinzón et al.,
2014). According to the relevance criteria for animal systems
summarized above, M. coucha permits the follow-up of the
complete infection cycle, starting from primary infection until
the development of lesions that are not restricted to a certain
body area (Nafz et al., 2007). Transcriptome analysis of skin
tumors lead to the identification of various mRNA isoforms of
MnPV (Salvermoser et al., 2016). Moreover, M. coucha-derived
cell lines (Hasche et al., 2016) can be used to test the effects of
additional factors on viral transcription and replication, making
previous drawbacks compared to mouse systems more and more
negligible.
Notably, the M. coucha model resembles in many
characteristics UV-induced NMSC development in humans. In a
large long-term study, the animals were irradiated with UV doses
that are comparable to different areas of the world (Hasche et al.,
2017). Naturally infected animals developed SCCs significantly
more often than virus-free controls. Some of these SCCs
were well differentiated and keratinizing (KSCCs), containing
high amounts of extrachromosomal and transcriptionally
active MnPV genomes as observed previously in spontaneous
MnPV-induced tumors (Amtmann et al., 1984; Vinzón et al.,
2014), whereas poorly differentiated and non-keratinizing SCCs
(nKSCCs) only contained low amounts or even lacked viral DNA.
Histologically KSCCs were similar to human AKs and Bowen’s
disease (Majores and Bierhoff, 2015) which also contain high
viral loads whereas SCCs usually lack HPV DNA (Weissenborn
et al., 2005). However, irrespective of the tumor type, all
tumor-bearing animals developed antibody responses against
the viral L1 capsid protein, providing evidence for preceding
infections, which again is seen in SCC patients (Andersson
et al., 2008). Notably, although showing the same time course of
induction, the histology of UV-induced SCCs was profoundly
influenced by the dose, with KSCCs mostly developing in the
lowest dose group and nKSCCs preferentially under higher
doses, pointing to the cumulative effect of UV causing human
FIGURE 1 | The preclinical animal model Mastomys coucha develops MnPV-induced skin lesions. (A) A young Mastomys coucha. (B) HE staining of a dysplastic
epithelium at the edge of a spontaneously emerging skin lesion. (C) Pan-cytokeratin staining shows the dysplasia of the epithelium. (D) In situ hybridization reveals
squamous cells positive for MnPV DNA.
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SCCs (Leiter and Garbe, 2008). Consequently, nKSCCs more
often harbored p53 mutants, especially at two hot-spots also
known from human SCCs (Pickering et al., 2014) and incapable
of activating expression of downstream targets. As shown in mice
before, a loss of functional p53 leads to less differentiated tumors
(Flores et al., 2016; Page et al., 2016) and induces cell migration
and degradation of the extracellular matrix (reviewed in Muller
et al., 2011). Since MnPV replication depends – like cutaneous
HPVs – on cell differentiation (reviewed in Doorbar et al., 2012),
this constellation can explain the loss of viral genomes in these
tumors by acquiring additional “driver” mutations (e.g., Trp53)
(Figure 2). Moreover, taking into account that more DNA
damages have been detected in MnPV-positive skin compared
to MnPV-negative skin, this model provided for the first time
evidence for a “hit-and-run mechanism” in a natural infection
system (Hasche et al., 2017).
FIGURE 2 | Suggested “hit-and-run” model based on experiments with Mastomys coucha. (A) Virus replication and virion formation depend on differentiating
squamous cells and are favored by UV-induced hyperproliferation. UV induces photoproducts, e.g., in Trp53. In uninfected cells, damages are repaired. In infected
cells, MnPV reduces chromosomal stability and inhibits DNA repair leading to an accumulation of mutations. (B) Altered squamous cells become neoplastic (light
blue) and start forming a well-differentiated keratinizing SCC, still representing a permissive system that allows viral replication and formation of virions. (C) When
neoplastic squamous cells accumulate further mutations (dark blue), a dedifferentiated phenotype (characterized by a switch from E-cadherin to vimentin expression)
is acquired, forming a poorly differentiated, non-keratinizing SCC (nKSCC). MnPV cannot replicate in this intracellular environment, resulting in a loss of viral DNA.
(Scheme modified from Hasche et al., 2017).
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Notably, a recent in vitro study showed that MnPV E6 does
not interact with E6AP, a prerequisite for p53 degradation,
but – like other cutaneous human and animal PVs – interacts
with MAML1 to inhibit NOTCH signaling (Brimer et al.,
2017). The same was reported for MmuPV1 E6, which also
inhibits differentiation of keratinocytes to keep the host cell in a
proliferative state (Meyers et al., 2017). However, to examine the
effect of UV exposure in the context of a cutaneous PV infection
requires more systematic studies, particularly to understand how
a single UV dose, shown to have immunosuppressive effects
(reviewed in Norval and Halliday, 2011), makes wildtype mice
susceptible to MmuPV1-induced tumors that can progress to
SCCs (Uberoi et al., 2016), while in other systems more frequent
exposure is necessary. This is an important point, especially for
immunosuppressed OTRs and the high incidence of NMSC in
these patients. However, the fundamental question is still how
cutaneous PVs contribute to tumor initiation and what kind of
selection mechanisms account for SCC formation and the loss of
viral DNA.
CURRENT WORK AND PERSPECTIVES
ON VACCINATION AGAINST
CUTANEOUS HPVS
The strongest argument for an etiological role of a virus in cancer
development is the application of a prophylactic vaccine that
prevents tumor formation. In the case of anogenital tumors, three
HPV vaccines (Cervarix, Gardasil, and Gardasil 9), consisting
of L1 (the major papillomavirus virion protein)-based virus-like
particles (VLPs) are currently licensed (Pogoda et al., 2016).
They are targeted against two, four, or nine mucosal HPV types
(HPV6, 11, 16, 18, 31, 33, 45, 52, and 58), respectively, and –
regardless of being very effective – they present limitations,
making the development of broad protective second-generation
HPV vaccines necessary. Most of the mechanistic studies showed
that vaccine-induced neutralizing antibodies are the primary
mediators of the elicited response, protecting from a subsequent
infection by the targeted HPV types and therefore conferring
immunity (Schiller and Lowy, 2012). Since the response has
been shown to be largely type-specific and cross-reactivity among
different HPV types is almost absent, these vaccines target, at
best, the high risk types that cause 90% of the cervical cancer
and no cutaneous types. Indeed, there are more than 40 HPV
types plausible of being targeted by a vaccine to prevent human
diseases: mucosal high-risk HPVs implied in the pathogenesis of
cervical and other cancers (HPV16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, 59, 68), additional mucosal types which cause genital
warts (HPV6 and 11), several beta HPV types potentially linked
to NMSC (HPV5, 8, 9, 12, 14, 15, 17, 19, 20, 21, 22, 23, 24, 25, 36,
37, 38, 47, 49) and the different alpha (HPV2, 3, 10, 27, 28, 57),
gamma (HPV4, 60, 65), mu (HPV1, 63), and nu (HPV41) types
that induce different lesions, being a special burden in children
and immunocompromised patients. Given the potential benefits
of covering so many different HPV types, a broad-protecting
prophylactic HPV vaccine is a rational goal for second-generation
vaccine development.
In this context, the papillomavirus minor capsid protein L2
contains a region with a major cross-neutralizing epitope that
has been the main immunogen for second-generation vaccines
(Gambhira et al., 2007). The goal of developing an L2-based
vaccine is to generate a single- or oligo-valent antigen with a
distinctively larger spectrum of protection against genital and
cutaneous HPVs than the current formulations (Pouyanfard
and Muller, 2017). Given that L2-derived linear peptides induce
antibody levels which are several orders of magnitude lower
that those induced by L1 VLP vaccines, different strategies had
been explored in order to achieve a successful immune response.
Among these, good responses were found by formation of L2
concatemers (Jagu et al., 2009), conjugation to a T-helper epitope
and a TLR ligand (Alphs et al., 2008), display on structures like
bacteriophages (Tumban et al., 2011) or on adeno-associated
viruses (Nieto et al., 2012), chimeric HPV L2 peptide/L1-VLPs
(Schellenbacher et al., 2009), integration into the thioredoxin
active site (Rubio et al., 2009) or lipidation and fusion to
FcγR-targeting scaffold (Zhang et al., 2016). These approaches
have shown elicitation of neutralizing antibodies with a broad
range of cross-neutralization, setting the proof-of-principle for
the application of this approach.
Several vaccine formulations, either L1- or L2-based, have
shown the development of antibodies neutralizing to PV
cutaneous types (summarized in Table 1), either by targeting
them directly or as a cross-protection. In particular, two studies
have shown the potential of these vaccines to effectively prevent
skin lesions in preclinical models. When M. coucha was used as a
model, a VLP-based vaccine against a cutaneous papillomavirus
could prevent spontaneous skin tumor formation both under
normal and immunosuppressed conditions (Vinzón et al.,
2014). As mentioned, MnPV-infected M. coucha resemble many
characteristics of cutaneous HPVs and the human situation,
like the natural and persistent infection early in life (Schäfer
et al., 2011). Assessing the efficacy of a VLP-based vaccine on
either previously or newly established infections, a long-lasting
response could be shown, characterized by the induction of
neutralizing antibodies that confer protection against both
benign and malignant skin tumors even in immunosuppressed
animals (Vinzón et al., 2014). Another novel finding of this
study was that protection involves the maintenance of a low viral
load in the skin by an antibody-dependent prevention of virus
spread and that it is effective in preventing tumor formation
even in individuals already infected at the time of vaccination.
These results offer evidence that VLPs elicit an effective immune
response in the skin even under immunosuppressed conditions,
irrespective of the infection status at the time of vaccination,
which sets the basis for a future clinical implementation of a
vaccine against cutaneous HPV-induced tumors to prevent SCCs,
especially in OTRs.
DNA vaccines were also explored in the context of cutaneous
HPV infection. A recent study (Marcuzzi et al., 2014) showed
that a vaccine consisting of HPV8 E6 DNA can generate a
specific cellular response in roughly half of the vaccinated
animals and partially prevent papilloma formation in those which
developed HPV8-E6-specific T cell immunity as demonstrated
by ELISPOT. Regarding L2 vaccines, a simple HPV16-L2 DNA
Frontiers in Microbiology | www.frontiersin.org 11 May 2018 | Volume 9 | Article 874
fmicb-09-00874 May 2, 2018 Time: 12:18 # 12
Hasche et al. Papillomaviruses and Non-melanoma Skin Cancer
TABLE 1 | Preclinical studies showing reactivity of HPV vaccines to cutaneous types/challenge.
Immunogen
scaffold/type
PV immunogen Cutaneous HPV
types neutralized by
the vaccine in vitro
HPV types
neutralized by
cutaneous challenge
Projected vaccine
development
Reference
VLPs L1 from HPV 5, 8, and 92 HPV 5 ND Unknown Handisurya et al., 2009
Capsomers/VLPs L1 from HPV 2, 27, and 57 HPV 2, 27, and 57 ND Unknown Senger et al., 2010
VLPs L1 from MnPV MnPV MnPV No Vinzón et al., 2014
Lipopeptide
(P25-P2C-HPV)
HPV16 L2(17–36) HPV 5, BPV 1 HPV 16 and 45 Unknown Alphs et al., 2008
L2 concatemers Fusion of the L2(11-88)
region of HPV types 6, 16,
18, 31, 39, 51, 56, and 73
HPV 3, 5, 8, 23, 27, 38,
57, 76
ND Unknown Kwak et al., 2014
Lipidated L2-repeat
fusioned to an
anti-hFcγRI scFv
HPV16 L2(17–36) HPV 2 and 5 ND Unknown Zhang et al., 2016
Chimeric VLPs HPV16 L2(17–36) HPV 2, 3, 5, 27, 76 ND Being produced under cGMP
for clinical trials by the NCI
PREVENT program (Shi et al.,
2001).
Schellenbacher et al.,
2009, 2013
Chimeric VLPs HPV17 L2(17–36) HPV 5, 20, 24, 38 and
96
HPV 5 Unknown Huber et al., 2017
Chimeric VLPs HPV 58 L2(16–37) HPV 2, 5, 27 and 57 ND Unknown Chen et al., 2017
Fusion to bacterial
flagellin
L2(11–200), L2(11–88)
and/or L2(17–38) of HPV 6,
16, 18, 31, 39 and 52
ND HPV 6, 16, 18, 31, 39,
52 and CRPV
Unknown Kalnin et al., 2014,
2017
Pyrococcus furiosus
thioredoxin with L2
octamer
L2(20–38) from HPV 6, 16,
18, 31, 33, 35, 51, and 59
HPV 3, 4, 5, 10, 38, 63,
76, 92, 95, and 96
ND Close to cGMP production for a
planned human trial
(Pouyanfard and Muller, 2017).
Pouyanfard et al., 2017;
Spagnoli et al., 2017
PP7/MS2
bacteriophage VLPs
HPV16 L2(20–29), (17–31),
(14–40) and (14–65)
ND HPV5 Being developed by the
company Agilvax with
DMID/NIAID/NIH support
(Pouyanfard and Muller, 2017).
Tumban et al., 2012
Naked-DNA, fusion to
calreticulin
MmuPV1 E6 and E7 and
L2(11–200)
ND ND Being produced under cGMP
for clinical trials by the NCI
PREVENT program (Shi et al.,
2001).
Jiang et al., 2017
vaccine showed no induction of neutralizing antibodies and
therefore no cross-reactivity potential (Hitzeroth et al., 2009). In
contrast, another vaccine composed of HPV16-L2/E6/E7 fused
to human calreticulin (hCRT) as a strategy to enhance MHC
class I presentation, induced both E6/E7-specific T-cell responses
and L2-specific neutralizing antibodies, showing both therapeutic
and prophylactic potential (Kim et al., 2008). hCRT-E6E7L2
conferred partial protection in an in vivo neutralization assay
(Jiang et al., 2017), but its cross-neutralization activity has not
been yet reported. Furthermore, when exploring the vaccine
in an immunosuppressed setting, hCRT-E6E7L2 vaccination
maintained cellular immune reactivity in CD4+ T cell-depleted
mice but lost the ability to induce a humoral response (Peng
et al., 2014). hCRT-E6E7L2 is currently produced under cGMP
for clinical trials by the NCI PREVENT program (Schellenbacher
et al., 2017).
The recent development in the MmuPV1 model allowed
vaccination studies also in this animal system (Jiang et al., 2017).
An hCRT-MmuPV1E6E7L2 DNA vaccine induced strong mE6
and mE7 CD8+ T cell responses and anti-L2 antibodies. In
addition to the vaccine-induced antibody titers, also a robust
anti-L1 response could be detected regardless of the papilloma
status of the animals, probably due to the inoculum used for
the experimental infection. Remarkably, persistent papillomas
disappeared within 2 months after treatment and the virus
could no longer be detected. Given the design of the vaccine,
the importance of neutralizing anti-L2 antibodies cannot be
dissected, as the anti-L2 response is concomitant to the E6 and
E7 responses.
Therefore, the effectivity of pure L2 vaccines in preventing
skin tumors is yet to be studied in a complete preclinical model.
One important issue to be answered is whether L2 vaccination
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can elicit enough neutralizing antibodies to confer protection
against tumor formation, especially against non-cognate HPV
types, since L2 responses are known to be lower than their
L1 counterparts. In that context, even when sera display titers
below detection limit by in vitro neutralization assays and in vivo
neutralization assays after passive transfer, vaccinated animals
still show complete protection against infection, which points
to the fact that very low titers are indeed sufficient to confer
immunity (Kalnin et al., 2017).
CONCLUSION
Current data strongly support an involvement of cutaneous
HPVs in the pathogenesis of NMSC. It is clear that a
vaccine targeting a broader spectrum, including mucosal and
cutaneous HPVs would be beneficial for certain patients,
especially those who are immunosuppressed. Since cutaneous
HPV infections are acquired very early in life, vaccination
in infancy seems to be most appropriate. The other option
would be the vaccination of immunocompromised individuals,
for example patients awaiting organ transplantation. By
eliminating one of the main risk factors (HPV infection), the
incidence of NMSC should be reduced. Clinical development
of vaccines that could achieve this goal is currently being
pursued.
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